A Phase 2/3 interventional study of Moxidectin and Ivermectin in Strongyloides Stercoralis Infection, sponsored by Jennifer Keiser. Completed at 1 site in Lao People's Democratic Republic. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by Jennifer Keiser · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia. The study aims at providing evidence on effective doses and safety of moxidectin in adults against infection with S. stercoralis in Laos (trial 2a) and efficacy and safety of moxidectin compared to ivermectin in adults against infection with S. stercoralis in Laos and Cambodia (trial 2b). The efficacy of the treatment will be assessed by collecting three stool samples once pre-treatment and once 21 days post-treatment. The stool samples will be analyzed by a quantitative Baermann assay.
This is a phase 2a single-blinded and a phase 2b double-blinded randomized clinical trial, which aims to determine efficacy and safety of (2a) seven ascending oral moxidectin dosages in 210 adults infected with S. stercoralis, namely placebo, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg in Lao and (2b) the recommended dose moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) in comparison to the standard treatment dose of ivermectin (200 µg/kg) in 350 adults infected with S. stercoralis in Lao and Cambodia. Embedded in the trial is a pharmacokinetic/-dynamic study with the goal to measure moxidectin disposition in adults and to determine population pharmacokinetic (PK) parameters of the optimal dose of moxidectin in the treatment of S. stercoralis.
The primary objective is to determine the dose-response of moxidectin based on cure rates (CR) against S. stercoralis and to quantify the efficacy of the recommended dose to the standard treatment (ivermectin) in adults.
The secondary objectives of the trial are: Evaluation of the safety and tolerability of the dose-dependent treatment regimes, evaluation of the safety and tolerability of moxidectin compared to ivermectin, comparison of the larvae reduction rate (LRR) of the different treatment regimens against S. stercoralis (trial 2a,b), determination of an exposure- (including Cmax, area under curve (AUC) and tmax) -response correlation of moxidectin in adults, comparison of the exposure-response of moxidectin using venous and capillary blood, evaluation of the cure rate of the different moxidectin treatment regimens against co-infection and the determination of the population PK parameters of the optimal dose of moxidectin in the treatment of S. stercoralis.
After obtaining informed consent from each individual, the medical history of the participants will be assessed with a standardized questionnaire, in addition to a clinical examination carried out by the study physician before treatment. Enrollment will be based on collection and analysis by a quantitative Baermann method (in duplicates) of three stool samples. Randomization of participants into the different treatment arms will be stratified according to intensity of infection. The adults will also be interviewed before treatment, 3 and 24 hours as well as 21 days after treatment about the occurrence of adverse events (AE). The efficacy of the treatment will be determined 21 days post-treatment by collecting another three stool samples. All stool samples will be examined with duplicate Baermann assays recorded quantitatively. Co-infection with T. trichiura, A. lumbricoides and hookworm infection will be identified using duplicate Kato-Katz thick smears on stool samples.
A subsample of adults will further be sampled using finger pricking for micro sampling at 0, 2, 4, 8, 24, and 72 hours, 7 and 21 days post treatment to evaluate pharmacokinetic parameters (trial phase 2a) and at defined time windows, that are based on the PK model earned from trial 2a (trial phase 2b). For validation of the analytical method the subsample of one study arm (8 mg, trial phase 2a) will undergo venous blood sampling in addition to finger pricking.
An available case analysis (full analysis set according to the intention to treat principle) will be performed, including all subjects with primary end point data. Supplementary, a per-protocol analysis will be conducted. CRs will be calculated as the percentage of larvae-positive subjects at baseline who become larvae-negative after treatment. Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))*100) Geometric and arithmetic mean larvae counts will be calculated for the different treatment arms before and after treatment to assess the corresponding LRRs. Bootstrap resampling method with 2,000 replicates will be used to calculate 95% confidence intervals (CIs) for LRRs. Emax models using the dose finding package of the statistical software environment R will be implemented to predict the dose-response curves in terms of CRs and LRRs.
Jennifer Keiser is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 mg Moxidectin at day 0 administered orally
Drug: Moxidectin
4 mg Moxidectin at day 0 administered orally
Drug: Moxidectin
6 mg Moxidectin at day 0 administered orally
Drug: Moxidectin
8 mg Moxidectin at day 0 administered orally
Drug: Moxidectin
10 mg Moxidectin at day 0 administered orally
Drug: Moxidectin
12 mg Moxidectin at day 0 administered orally
Drug: Moxidectin
matching Placebo tablet(s) at day 0 administered orally
Drug: Placebo oral tablet
the recommended dose moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally + Ivermectin placebo, corresponding to Phase 2b - Arm B
Drug: Moxidectin
200 µg/kg ivermectin at day 0 administered orally + Moxidectin placebo, corresponding to Phase 2b - Arm A
Drug: Ivermectin
Monotherapy, oral administration, single dose, fixed dose
Monotherapy, oral administration, single dose, weight dependent
Monotherapy, oral administration, single dose, matching number of tablets
Observed Cure Rate Against Strongyloides Stercoralis
The conversion from being larvae positive pre-treatment to larvae negative post-treatment, or cure rate (CR).
Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Observed Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis
Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))\*100)
Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides
CRs will be calculated for Ascaris lumbricoides infections as described in primary outcome.
Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura
CRs will be calculated for Trichuris trichiura infections as described in primary outcome.
Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm
CRs will be calculated for Hookworm infections as described in primary outcome.
Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Number of Participants Reporting Adverse Events
Subjects will be kept for observation for at least 3 hours following treatment for any acute AEs. If there is any abnormal finding, the local study physician will perform a full clinical, physical and biochemical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. In addition patients will also be interviewed 2-3 and 24 hours and again 3-4 (phase 2a) or 2-3 (phase 2b) weeks after treatment about the occurrence of AEs. A standardized symptom questionnaire is used, that includes the recording of headache, abdominal pain, itching, nausea, vomiting, diarrhea, allergic reaction as well as any further mentioned event by the participant.
Time frame: 2-3 hours, 24 hours, and retrospectively 21-28 days (phase 2a) or 14-21 days (phase 2b Arm A and Arm B) after treatment.
Maximum Concentration (Cmax) of Moxidectin in Adults
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
Time to Reach Cmax (Tmax) of Moxidectin in Adults
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
Area Under the Curve (AUC) of Moxidectin in Adults
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
Elimination Half Life (T1/2) of Moxidectin in Adults
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
| Milestone | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 31 | 33 | 33 | 32 | 32 | 30 | 32 | 0 | 0 |
| Completed | 30 | 29 | 32 | 29 | 30 | 30 | 29 | 0 | 0 |
| Not completed | 1 | 4 | 1 | 3 | 2 | 0 | 3 | 0 | 0 |
| Milestone | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 197 | 197 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 192 | 189 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 |
The conversion from being larvae positive pre-treatment to larvae negative post-treatment, or cure rate (CR).
| percentage of participants | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Observed Cure Rate Against Strongyloides Stercoralis | 73.3 (54.1 to 87.7) | 89.7 (72.6 to 97.8) | 84.4 (67.2 to 94.7) | 82.8 (64.2 to 94.2) | 96.6 (82.2 to 99.9) | 87.1 (70.2 to 96.4) | 13.8 (3.9 to 31.7) | 92.7 (88.1 to 96.0) | 92.6 (87.9 to 95.9) |
Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))\*100)
| percent change | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm A (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Observed Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis | 98.4 (93.7 to 99.9) | 99.4 (98.1 to 100) | 99.8 (99.3 to 100) | 97.8 (93.2 to 99.9) | 98.6 (95.1 to 100) | 98.5 (95.6 to 99.9) | 27.0 (-2.2 to 48.3) | 99.6 (99.1 to 100) | 99.9 (99.8 to 100) |
CRs will be calculated for Ascaris lumbricoides infections as described in primary outcome.
| percentage of participants | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides | — | 0 (0 to 0) | 100 (100 to 100) | 100 (100 to 100) | 100 (100 to 100) | 0 (0 to 0) | — | 100 (100 to 100) | 83.3 (40.5 to 100) |
CRs will be calculated for Trichuris trichiura infections as described in primary outcome.
| percentage of participants | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura | 100 | 100 | 50 | 33 | 0 | 0 | 0 | 100 | 100 |
CRs will be calculated for Hookworm infections as described in primary outcome.
| percentage of participants | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm | 0 | 11 | 14 | 0 | 10 | 29 | 0 | 31.9 | 17.5 |
Subjects will be kept for observation for at least 3 hours following treatment for any acute AEs. If there is any abnormal finding, the local study physician will perform a full clinical, physical and biochemical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. In addition patients will also be interviewed 2-3 and 24 hours and again 3-4 (phase 2a) or 2-3 (phase 2b) weeks after treatment about the occurrence of AEs. A standardized symptom questionnaire is used, that includes the recording of headache, abdominal pain, itching, nausea, vomiting, diarrhea, allergic reaction as well as any further mentioned event by the participant.
| Participants | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| 2-3 hours: Headache | 1 | 1 | 1 | 1 | 2 | 0 | 5 | 11 | 9 |
| 2-3 hours: Abdominal pain | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 12 | 10 |
| 2-3 hours: Itching | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 4 |
| 2-3 hours: Nausea | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| 2-3 hours: Vomiting | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-3 hours: Diarrhea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-3 hours: Allergic reaction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 hours: Headache | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 12 |
| 24 hours: Abdominal pain | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 21 |
| 24 hours: Itching | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 |
| 24 hours: Nausea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| 24 hours: Vomiting | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 6 |
| 24 hours: Diarrhea | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 3 |
| 24 hours: Allergic reaction | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 21-28/14-21 days: Headache | 2 | 1 | 1 | 2 | 2 | 1 | 2 | 8 | 1 |
| 21-28/14-21 days: Abdominal pain | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 5 |
| 21-28/14-21 days: Itching | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 9 | 1 |
| 21-28/14-21 days: Nausea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| 21-28/14-21 days: Vomiting | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 21-28/14-21 days: Diarrhea | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 2 |
| 21-28/14-21 days: Allergic reaction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
| ng/mL | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of Moxidectin in Adults | — | — | — | 86.1 (76.7 to 89.5) | — | — | — | — | — |
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
| hours | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) of Moxidectin in Adults | — | — | — | 4 (4 to 4) | — | — | — | — | — |
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
| ng/mL*h | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve (AUC) of Moxidectin in Adults | — | — | — | 5028 (4286 to 5578) | — | — | — | — | — |
Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.
| hours | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| Elimination Half Life (T1/2) of Moxidectin in Adults | — | — | — | 666 (562 to 759) | — | — | — | — | — |
Collected over 21-28 days (phase 2a) / 14-21 days (phase 2b). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2a - Arm A (Moxidectin 2 mg) | 0/31 (0%) | 0/31 (0%) | 3/31 (9.7%) |
| Phase 2a - Arm B (Moxidectin 4 mg) | 0/33 (0%) | 0/33 (0%) | 6/33 (18.2%) |
| Phase 2a - Arm C (Moxidectin 6 mg) | 0/33 (0%) | 0/33 (0%) | 3/33 (9.1%) |
| Phase 2a - Arm D (Moxidectin 8 mg) | 0/32 (0%) | 0/32 (0%) | 5/32 (15.6%) |
| Phase 2a - Arm E (Moxidectin 10 mg) | 0/32 (0%) | 0/32 (0%) | 7/32 (21.9%) |
| Phase 2a - Arm F (Moxidectin 12 mg) | 0/30 (0%) | 0/30 (0%) | 1/30 (3.3%) |
| Phase 2a - Arm G (Placebo) | 0/32 (0%) | 0/32 (0%) | 12/32 (37.5%) |
| Phase 2b - Arm A (Moxidectin) | 0/197 (0%) | 0/197 (0%) | 59/197 (29.9%) |
| Phase 2b - Arm B (Ivermectin) | 0/197 (0%) | 0/197 (0%) | 60/197 (30.5%) |
| Event | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheGeneral disorders | 3/31 | 2/33 | 2/33 | 3/32 | 4/32 | 1/30 | 8/32 | 25/197 | 21/197 |
| Abdominal painGastrointestinal disorders | 0/31 | 0/33 | 0/33 | 0/32 | 2/32 | 0/30 | 1/32 | 41/197 | 34/197 |
| ItchingSkin and subcutaneous tissue disorders | 0/31 | 2/33 | 1/33 | 0/32 | 0/32 | 0/30 | 1/32 | 15/197 | 8/197 |
| DiarrheaGastrointestinal disorders | 1/31 | 2/33 | 0/33 | 1/32 | 1/32 | 0/30 | 1/32 | 2/197 | 5/197 |
| VomitingGastrointestinal disorders | 0/31 | 0/33 | 0/33 | 0/32 | 0/32 | 0/30 | 1/32 | 7/197 | 6/197 |
| NauseaGeneral disorders | 0/31 | 0/33 | 0/33 | 0/32 | 0/32 | 0/30 | 1/32 | 6/197 | 2/197 |
| Allergic reactionGeneral disorders | 0/31 | 0/33 | 0/33 | 1/32 | 0/32 | 0/30 | 0/32 | 0/197 | 3/197 |
| Age, Continuous(years) | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 41.6 ± 10.7 | 46.3 ± 12.5 | 45.3 ± 11.8 | 44.0 ± 13.5 | 44.4 ± 11.8 | 44.3 ± 11.2 | 40.0 ± 10.7 | 45.4 ± 11.6 | 44.8 ± 11.1 | 45.1 ± 11.3 |
| Sex: Female, Male(Participants) | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 12 | 8 | 10 | 9 | 13 | 9 | 10 | 89 | 94 | 254 |
| Male | 18 | 21 | 22 | 20 | 17 | 21 | 19 | 108 | 103 | 349 |
| Race and Ethnicity Not Collected(Participants) | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | — | — | — | — | 0 |
| Region of Enrollment(participants) | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Laos | 31 | 33 | 33 | 32 | 32 | 30 | 32 | 197 | 197 | 617 |
| Strongyloides stercoralis infection intensity(Participants) | Phase 2a - Arm A (Moxidectin 2 mg) | Phase 2a - Arm B (Moxidectin 4 mg) | Phase 2a - Arm C (Moxidectin 6 mg) | Phase 2a - Arm D (Moxidectin 8 mg) | Phase 2a - Arm E (Moxidectin 10 mg) | Phase 2a - Arm F (Moxidectin 12 mg) | Phase 2a - Arm G (Placebo) | Phase 2b - Arm A (Moxidectin) | Phase 2b - Arm B (Ivermectin) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Light | 6 | 4 | 6 | 3 | 5 | 3 | 4 | 47 | 53 | 131 |
| Moderate | 13 | 13 | 14 | 12 | 12 | 13 | 12 | 85 | 83 | 257 |
| Heavy | 11 | 12 | 12 | 14 | 13 | 14 | 13 | 65 | 61 | 215 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2019 to primary completion in Apr 2021, 17 months.
Results were first posted in Dec 2024, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxidectin
Jennifer Keiser